Abbott Reports In-Line Q1 Results, Updates FY26 Guidance Post-Exact Sciences Acquisition
ABT is trading near its 52-week low of $99.05 (0.2% above the low).
Summary
Abbott Laboratories reported first-quarter results aligned with expectations and updated its full-year guidance, incorporating the financial impact of the recently completed Exact Sciences acquisition.
Key Events · Earnings and Guidance · ABT
-
First-Quarter 2026 Results Announced
Abbott reported first-quarter GAAP diluted EPS of $0.61 and adjusted diluted EPS of $1.15, reflecting 6 percent growth. Sales increased 7.8 percent on a reported basis and 3.7 percent on a comparable basis, aligning with expectations.
-
Full-Year 2026 Guidance Updated
The company projects full-year 2026 comparable sales growth of 6.5% to 7.5% and adjusted diluted EPS of $5.38 to $5.58. This guidance includes a $0.20 per share dilution related to the Exact Sciences acquisition.
-
Exact Sciences Acquisition Completed
Abbott completed its acquisition of Exact Sciences on March 23, 2026, establishing a leadership position in the oncology diagnostics market and adding a new high-growth vertical to its portfolio.
-
Positive Product Development Updates
Abbott announced a collaboration for a next-generation EV-ICD system, positive early results for the Amulet 360™ Left Atrial Appendage Occluder, and clinically meaningful HbA1c reduction with FreeStyle Libre® in Type 2 diabetes patients.
Analysis · ABT · Life Sciences
This filing provides Abbott's official first-quarter results, which were aligned with expectations. Crucially, it updates the full-year 2026 financial guidance to reflect the recently completed Exact Sciences acquisition, quantifying its dilutive impact while maintaining a positive outlook for accelerating growth. This clarity on future performance, combined with positive product development news, is important for investors, especially with the stock trading near its 52-week low, as it provides a baseline for future valuation.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 29.5% of the 1626 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABT was trading at $99.25 on NYSE in the Life Sciences sector, with a market capitalization of approximately $176.9B. The 52-week trading range was $99.05 to $139.06. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.